Published in Aliment Pharmacol Ther on December 01, 2005
GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation ) | NCT02994836
Tight Control Management in Perianal Crohn's Disease (PLACE-PCD) | NCT03861689
Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol (2008) 1.52
Emerging treatments for complex perianal fistula in Crohn's disease. World J Gastroenterol (2009) 1.15
Prevention of post-operative recurrence of Crohn's disease. World J Gastroenterol (2014) 0.84
Recent developments in the surgical management of perianal fistula for Crohn's disease. Ann Gastroenterol (2014) 0.83
Abdominal sonographic changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's Disease. Dig Dis Sci (2009) 0.82
Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics (2009) 0.81
Health care costs of complex perianal fistula in Crohn's disease. Dig Dis Sci (2013) 0.79
Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterol Res Pract (2015) 0.79
Surgical strategies in paediatric inflammatory bowel disease. World J Gastroenterol (2015) 0.77
The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol (2016) 0.77
Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World J Gastroenterol (2015) 0.76
Imaging techniques and combined medical and surgical treatment of perianal Crohn's disease. J Ultrasound (2013) 0.76
The role of ABO blood groups in Crohn's disease and in monitoring response to infliximab treatment. Blood Transfus (2016) 0.75
Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. Am J Gastroenterol (2016) 0.75
Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers. BMC Med Imaging (2016) 0.75
The long-term outcome of anti-TNF alpha therapy in perianal Crohn's disease. Tech Coloproctol (2017) 0.75
A simple method of measuring breath hydrogen in carbohydrate malabsorption by end-expiratory sampling. Clin Sci Mol Med (1976) 3.87
Dietary fibres, fibre analogues, and glucose tolerance: importance of viscosity. Br Med J (1978) 3.54
Unabsorbable carbohydrates and diabetes: Decreased post-prandial hyperglycaemia. Lancet (1976) 2.84
Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology (1994) 2.27
Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology (2000) 2.22
ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr (2006) 2.11
Breath-hydrogen test for small-intestinal bacterial colonisation. Lancet (1976) 2.09
Decrease in postprandial insulin and glucose concentrations by guar and pectin. Ann Intern Med (1977) 2.01
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 1.87
Letter: Dietary fibre redefined. Lancet (1976) 1.80
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther (2011) 1.63
Surgical treatment of isolated and syndromic craniosynostosis. Results and complications in 283 consecutive cases. Neurocirugia (Astur) (2008) 1.61
Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology (1990) 1.59
Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther (2009) 1.52
[Autoimmune hemolytic anemia associated with ulcerative colitis]. Gastroenterol Hepatol (2005) 1.44
Adverse effects of azathioprine in the treatment of inflammatory bowel disease. Rev Esp Enferm Dig (2001) 1.44
Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev Esp Enferm Dig (2004) 1.44
Letter: Metabolic effects of bran. Br Med J (1976) 1.38
[Efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease]. Rev Esp Enferm Dig (1995) 1.38
[Gasometric alterations in hospitalized cirrhotic patients]. An Med Interna (2005) 1.38
[Prophylactic sclerosis of esophageal varices. Results of a controlled prospective study]. Med Clin (Barc) (1991) 1.37
Methane production and colon cancer. Gastroenterology (1984) 1.31
Vitamin status in patients with inflammatory bowel disease. Am J Gastroenterol (1989) 1.27
Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology (2000) 1.23
Effect of dietary fiber on complications of gastric surgery: prevention of postprandial hypoglycemia by pectin. Gastroenterology (1977) 1.21
Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol (1999) 1.19
Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. J Hepatol (1998) 1.19
Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther (2004) 1.18
Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. J Infect Dis (1998) 1.15
Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol (1999) 1.14
Relationship between smoking and colonic involvement in inflammatory bowel disease. Rev Esp Enferm Dig (1998) 1.14
Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther (2007) 1.12
Plasma polyunsaturated fatty acid pattern in active inflammatory bowel disease. Gut (1992) 1.10
Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis. Gut (1994) 1.08
Changes of the mucosal n3 and n6 fatty acid status occur early in the colorectal adenoma-carcinoma sequence. Gut (1996) 1.08
Triazidocobalt(III) complexes with tridentate amine ligands. Acta Crystallogr C (2000) 1.08
Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut (1993) 1.06
Sugar malabsorption in functional bowel disease: clinical implications. Am J Gastroenterol (1993) 1.06
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. Clin Exp Immunol (2013) 1.06
Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. Am J Gastroenterol (1993) 1.04
Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology (2000) 1.04
How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. JPEN J Parenter Enteral Nutr (1996) 1.03
Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2005) 1.00
A randomized, placebo-controlled study of donepezil in poststroke aphasia. Neurology (2006) 1.00
Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology (1994) 0.98
Enteral nutrition in inflammatory bowel disease. Gut (1986) 0.97
Serological markers and HLA-DQ2 haplotype among first-degree relatives of celiac patients. Catalonian Coeliac Disease Study Group. Dig Dis Sci (1999) 0.97
Lack of effect of refining on the glycemic response to cereals. Diabetes Care (1982) 0.96
Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability. Aliment Pharmacol Ther (2009) 0.95
Serum selenium and risk of large size colorectal adenomas in a geographical area with a low selenium status. Am J Gastroenterol (2002) 0.95
Protein-energy malnutrition: an integral approach and a simple new classification. Hum Nutr Clin Nutr (1984) 0.94
Enteral nutrition as primary therapy in Crohn's disease. Gut (1994) 0.93
Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of Child-Pugh score in nonbleeding advanced cirrhotics. Am J Gastroenterol (1993) 0.93
Anorectal function in patients with complete rectal prolapse. Differences between continent and incontinent individuals. Rev Esp Enferm Dig (1998) 0.92
Complications of enteral feeding. Nutrition (1993) 0.92
Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn's disease. Int Immunol (2004) 0.92
Direct phase determination from neutron diffraction data of the structure of melampodin. Science (1972) 0.91
Hypertransaminasemia in pediatric celiac disease patients and its prevalence as a diagnostic clue. Am J Gastroenterol (2002) 0.90
Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis (2001) 0.90
A mixture of Lactobacillus plantarum CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial. Nutr Hosp (2011) 0.90
Changes in mucosal fatty acid profile in inflammatorybowel disease and in experimental colitis: a common response to bowel inflammation. Clin Nutr (1997) 0.89
Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. Aliment Pharmacol Ther (2013) 0.89
Effects of a weighted vest on attention to task and self-stimulatory behaviors in preschoolers with pervasive developmental disorders. Am J Occup Ther (2003) 0.88
Letter: Food: influence of form on absorption. Lancet (1975) 0.88
Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol (1993) 0.88
[Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease]. Gastroenterol Hepatol (2006) 0.88
Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol (1997) 0.88